Skip to Content
Merck
  • Interception of host fatty acid metabolism by mycobacteria under hypoxia to suppress anti-TB immunity.

Interception of host fatty acid metabolism by mycobacteria under hypoxia to suppress anti-TB immunity.

Cell discovery (2021-10-06)
Hua Yang, Fei Wang, Xinya Guo, Feng Liu, Zhonghua Liu, Xiangyang Wu, Mengmeng Zhao, Mingtong Ma, Haipeng Liu, Lianhua Qin, Lin Wang, Tianqi Tang, Wei Sha, Yang Wang, Jianxia Chen, Xiaochen Huang, Jie Wang, Cheng Peng, Ruijuan Zheng, Fen Tang, Lu Zhang, Chunyan Wu, Stefan H Oehlers, Zhigang Song, Jialei She, Hua Feng, Xunwei Xie, Baoxue Ge
ABSTRACT

Pathogenic mycobacteria induce the formation of hypoxic granulomas during latent tuberculosis (TB) infection, in which the immune system contains, but fails to eliminate the mycobacteria. Fatty acid metabolism-related genes are relatively overrepresented in the mycobacterial genome and mycobacteria favor host-derived fatty acids as nutrient sources. However, whether and how mycobacteria modulate host fatty acid metabolism to drive granuloma progression remains unknown. Here, we report that mycobacteria under hypoxia markedly secrete the protein Rv0859/MMAR_4677 (Fatty-acid degradation A, FadA), which is also enriched in tuberculous granulomas. FadA acts as an acetyltransferase that converts host acetyl-CoA to acetoacetyl-CoA. The reduced acetyl-CoA level suppresses H3K9Ac-mediated expression of the host proinflammatory cytokine Il6, thus promoting granuloma progression. Moreover, supplementation of acetate increases the level of acetyl-CoA and inhibits the formation of granulomas. Our findings suggest an unexpected mechanism of a hypoxia-induced mycobacterial protein suppressing host immunity via modulation of host fatty acid metabolism and raise the possibility of a novel therapeutic strategy for TB infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyl 2,4-dibromobutyrate, ≥97.0% (GC)